Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TN-001 eyedrops in progressive keratoconus
NCT07388069Phase 2Enrolling by invitation
- Sponsor
- TheiaNova
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TN-001 in keratoconus (2 arms), sponsored by TheiaNova. Primary endpoints: Participant-reported ocular tolerability score at 180 days, Incidence of ocular and peri-ocular inflammation by slit-lamp examination at 180 days and 9 more. Started Dec 2025; status: enrolling by invitation.
02
Drugs
TN-001
03
Conditions
keratoconus
Beyond the preview
Go deeper on NCT07388069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388069.